產學研發-EN – 【國家衛生研究院】技轉及育成中心

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Latest news-English, Uncategorized, 技術-EN, 技術轉移招商en文章, 產學研發徵求夥伴en文章 / 2022 年 7 月 26 日 2022 年 7 月 26 日

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26 1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: DBPR807 is a small molecule CXCR4 antagonist. DBPR807 can significantly suppress tumor growth of hepatocellular carcinoma via reducing angiogenesis, …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

Latest news-English, Latest news-English, 技術轉移招商en文章 / 2022 年 1 月 3 日 2022 年 1 月 3 日

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”（2018/12/17）

技術-EN, 產學研發-EN, 產學研發-EN, 產學研發-EN / 2018 年 12 月 17 日 2021 年 9 月 2 日

Title: NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”（2018/12/17） Read More »